Trials / Conditions / Myxovirus Infection

Myxovirus Infection

12 registered clinical trials studyying Myxovirus Infection.

Status	Trial	Sponsor	Phase
Completed	Influenza Vaccine Revaccination in Ambulatory Elderly Subjects NCT00775450	Sanofi Pasteur, a Sanofi Company	Phase 2
Completed	Study of Fluzone Vaccine Administered by Intradermal Route in Comparison With Standard Fluzone® in Adults NCT00772109	Sanofi Pasteur, a Sanofi Company	Phase 3
Completed	Study of Inactivated, Split-Virion Influenza Vaccine and Standard Fluzone® Vaccine in Adult and Elderly Subjec NCT00551031	Sanofi	Phase 2
Completed	Immunogenicity of a Split, Cell-Based, Inactivated, Trivalent Influenza Vaccine in Healthy Adult Subjects NCT00845429	Sanofi	Phase 2
Completed	Study of Immune Response in Adults and Elderly Subjects Vaccinated With Inactivated Influenza Vaccines NCT00776438	Sanofi Pasteur, a Sanofi Company	Phase 2
Completed	Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Infants and Chi NCT00391391	Sanofi	Phase 2
Completed	Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the NCT00391053	Sanofi Pasteur, a Sanofi Company	Phase 3
Completed	Lot-to-Lot Consistency Study of the Investigational, Inactivated, Split-Virion Influenza Vaccine in Adults NCT00383539	Sanofi Pasteur, a Sanofi Company	Phase 3
Completed	Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Elderly Subject NCT00388583	Sanofi	Phase 2
Completed	Study of Inactivated, Split-Virion Influenza Vaccine Compared With the Reference Vaccine Vaxigrip® in the Elde NCT00383526	Sanofi Pasteur, a Sanofi Company	Phase 3
Completed	Immunogenicity of Two Dosages of Inactivated, Split-Virion Influenza Vaccine Given by an Alternate Route in th NCT00296829	Sanofi Pasteur, a Sanofi Company	Phase 2
Completed	Study of Inactivated, Split-Virion Influenza Vaccine Administered by Intradermal Route Versus Vaxigrip® in Adu NCT00703651	Sanofi Pasteur, a Sanofi Company	Phase 2